Phase II data bring Blueprint closer to major market expansion for Ayvakit
With positive initial data for Ayvakit in indolent systemic mastocytosis, Blueprint is moving into position to expand its only approved drug into a much larger patient population while sticking to its strategy of focusing on genetically defined subsets of cancer and rare diseases.
Blueprint Medicines Corp. (NASDAQ:BPMC) presented data from the first, dose-finding part of its Phase II PIONEER trial at the American Academy of Allergy, Asthma & Immunology (AAAAI) virtual forum on Monday, showing that the lowest dose of Ayvakit avapritinib reduced symptoms and improved quality of life...
BCIQ Company Profiles
BCIQ Target Profiles
Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117)